Patron Exim Ltd is a ₹7.16 crore market cap BSE SME-listed microcap trading at ₹3.09, which is somehow 0.18× book value and still manages to look expensive emotionally. Sales are ₹48.08 crore (TTM), PAT is ₹0.33 crore, and ROE is a heroic 0.18% — the kind of return your savings account laughs at.
The latest half-year (H1 FY26, Sept 2025) shows ₹23.72 crore revenue and a net profit of ₹0.01 crore. Yes, that’s ₹1 lakh. Promoters? They rage-quit the cap table, dropping holding from 71.18% to 20.03% in one quarter.
This stock is cheap, illiquid, chaotic, and comes with auditor red flags, governance footnotes, and cash flows that vanish faster than IPO optimism. If balance sheets could scream, this one would be hoarse already.
2. Introduction – From Timber to APIs to “Arey Yeh Kya Hai?”
Founded in 1992, Patron Exim has lived multiple lives. Timber trader. Cement sheets. Surgical goods. And now — pharma APIs, excipients, solvents, petrochemicals, dyes, agro chemicals, resins, polymers… basically a chemical buffet where everything is on the menu but margins are missing.
The company positions itself as an ISO-certified, WHO-GMP compliant trader. Sounds premium, right? But scratch the surface and you realise this is not a manufacturer, not a formulators’ darling, not a brand — just a trading desk with invoices and razor-thin spreads.
Revenue looks big for the market cap, but profits are allergic to consistency. One year you get other income saving the P&L, next year operating margins go negative like a meme stock.
And then comes the plot twist: the promoters leave the building. Not slowly. Not gracefully. A full Bollywood-style interval exit.
So the question isn’t “why is the stock cheap?” The question is: why is it even alive?
3. Business Model – WTF Do They Even Do?
Patron Exim is a pure trading company. No factories. No R&D. No product moat.
They buy and sell:
APIs & excipients
Pharma intermediates
Petrochemicals
Dyes & pigments
Agro chemicals
Resins, polymers, additives
Food & water treatment chemicals
Roughly 150+ products, zero pricing power. This is not pharma — this is commodity trading wearing a lab coat.
Revenue split (FY23):
Sale of products: ~69%
Other income: ~31%
Any business where one-third of revenue is “other income” deserves a pause and a raised eyebrow. Trading margins are sub-1%, working capital is huge, and survival depends on receivables behaving — which historically, they didn’t.
This is not a growth story. This is a spread survival story.
